Promising Development in Alzheimer's Treatment: FDA Accepts Leqembi ® (Lecanemab-Irmb) sBLA for IV Maintenance Dosing
Monday, 10 June 2024, 00:08
Promising Development in Alzheimer's Treatment
The FDA's acceptance of the filing of Leqembi ® (lecanemab-irmb) sBLA for IV maintenance dosing marks a significant milestone
New Possibilities for Patients and Healthcare Providers
- Offers hope for improved outcomes
- Potential advancements in the field
With this acceptance, the door is now open for further evaluation and potential approval
Bringing renewed focus and optimism to the fight against Alzheimer's.This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.